1. Home
  2. CVE vs ALNY Comparison

CVE vs ALNY Comparison

Compare CVE & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CVE
  • ALNY
  • Stock Information
  • Founded
  • CVE 2009
  • ALNY 2002
  • Country
  • CVE Canada
  • ALNY United States
  • Employees
  • CVE N/A
  • ALNY N/A
  • Industry
  • CVE Oil & Gas Production
  • ALNY Biotechnology: Pharmaceutical Preparations
  • Sector
  • CVE Energy
  • ALNY Health Care
  • Exchange
  • CVE Nasdaq
  • ALNY Nasdaq
  • Market Cap
  • CVE 27.8B
  • ALNY 33.1B
  • IPO Year
  • CVE N/A
  • ALNY 2004
  • Fundamental
  • Price
  • CVE $14.84
  • ALNY $245.79
  • Analyst Decision
  • CVE Buy
  • ALNY Buy
  • Analyst Count
  • CVE 4
  • ALNY 23
  • Target Price
  • CVE $30.00
  • ALNY $298.59
  • AVG Volume (30 Days)
  • CVE 7.9M
  • ALNY 621.3K
  • Earning Date
  • CVE 02-13-2025
  • ALNY 02-13-2025
  • Dividend Yield
  • CVE 3.45%
  • ALNY N/A
  • EPS Growth
  • CVE N/A
  • ALNY N/A
  • EPS
  • CVE 1.47
  • ALNY N/A
  • Revenue
  • CVE $41,204,337,672.00
  • ALNY $2,094,795,000.00
  • Revenue This Year
  • CVE $11.65
  • ALNY $25.14
  • Revenue Next Year
  • CVE N/A
  • ALNY $17.35
  • P/E Ratio
  • CVE $10.07
  • ALNY N/A
  • Revenue Growth
  • CVE 4.77
  • ALNY 21.54
  • 52 Week Low
  • CVE $14.55
  • ALNY $141.98
  • 52 Week High
  • CVE $21.90
  • ALNY $304.39
  • Technical
  • Relative Strength Index (RSI)
  • CVE 35.18
  • ALNY 40.54
  • Support Level
  • CVE $14.55
  • ALNY $240.42
  • Resistance Level
  • CVE $16.62
  • ALNY $249.58
  • Average True Range (ATR)
  • CVE 0.39
  • ALNY 6.10
  • MACD
  • CVE -0.04
  • ALNY 0.15
  • Stochastic Oscillator
  • CVE 11.35
  • ALNY 31.84

About CVE Cenovus Energy Inc

Cenovus Energy Inc is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 786 thousand barrels of oil equivalent per day in 2022. The company had upstream projects across Western Canada; crude oil production and natural gas and NGLs production offshore China and Indonesia. The downstream operations include upgrading and refining operations in Canada and the U.S., and commercial fuel operations across Canada.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: